How is Eli Lilly Innovating in Obesity Treatments?

On December 22, 2025, Novo Nordisk announced that their Wegovy pill will hit pharmacy shelves on January 5th as the first GLP-1 weight-loss medication in oral form, with the aim of delivering approximately 14 percent average weight loss at a monthly cost between $149 and $299. Two weeks later, on January 6, 2026, Eli Lilly announced it was deepening its commitment to computational drug discovery by partnering with Nimbus Therapeutics to develop a novel oral obesity treatment, with a deal potentially worth $1.3 billion, as reported by Reuters.

The timing is everything. Lilly's own oral candidate, orforglipron, is expected to receive FDA approval by March 2026. But rather than relying solely on orforglipron to dominate the obesity market, Lilly is hedging by funding Nimbus to discover entirely new small-molecule obesity drugs using AI-driven computational chemistry.

In a market that could exceed $150 billion annually by the early 2030s, betting on a single molecule is insufficient. Betting on a discovery platform, one that has already proven it can solve "difficult-to-drug" problems, is insurance.

"We are pleased to deepen our collaboration with Nimbus, a team that has demonstrated exceptional ability to tackle complex drug discovery challenges," Ruth Gimeno, Group Vice President of Diabetes and Metabolic Research and Development at Lilly, said in a statement.

Lilly and Nimbus have partnered before. In 2022, they entered a research and licensing agreement targeting AMPK activation for cardiometabolic diseases worth up to $496 million. That collaboration recently produced a breakthrough.

In February 2025, Nimbus announced it had solved a "decades-old challenge in drug development" by discovering a highly selective, isoform-specific AMPK activator, the kind of precision molecular design that typically takes pharmaceutical companies years of trial and error to accomplish.

The Computational Bet

Nimbus doesn't operate like traditional pharmaceutical companies. The Boston-based biotech combines computational scientists, medicinal chemists, pharmacologists, and translational biologists to integrate AI-driven predictive models with structure-based design. The outcome is molecules optimized for targets that have historically resisted small-molecule drug design.

The most compelling validation of Nimbus's computational approach came from an unexpected source. In 2022, Takeda Pharmaceutical acquired one of Nimbus's discoveries, a tyrosine kinase 2 (TYK2) inhibitor, for up to $4 billion. In December 2025, that molecule, now called zasocitinib, cleared two late-stage clinical trials for psoriasis treatment, and Takeda announced plans to seek regulatory approval in 2026. A molecule discovered through Nimbus's computational platform was validated in real patients, at scale, in a competitive therapeutic area. That success is now the case study Lilly is banking on.

Under the new agreement with Lilly, Nimbus receives $55 million in upfront and near-term milestone payments, with potential for up to $1.3 billion in development, commercial, and sales milestones, plus tiered royalties on global net sales. Lilly has licensed Nimbus's computational technology on an exclusive, worldwide basis for this obesity program.

Lilly's bet makes strategic sense when viewed against its own obesity pipeline. Orforglipron, Lilly's flagship oral obesity candidate, has demonstrated compelling clinical data. At its highest dose (36 milligrams), orforglipron achieves approximately 12.4 percent average weight loss, data from Phase 3 trials showed 73.6 percent greater relative weight loss compared to oral semaglutide (which showed 5.3 percent weight loss). More importantly, orforglipron can be taken at any time of day without food or water restrictions, unlike oral semaglitide, which requires a 30-minute fasting window.

This operational advantage matters enormously for patient behavior and adherence. Weight-loss medications are notoriously difficult to stay on with gastrointestinal side effects, inconvenience, and motivation drift all drive discontinuation. A daily pill taken without food restrictions has inherent behavioral advantages. Analysts expect orforglipron to become a mega-blockbuster, with GlobalData forecasting $13 billion in annual sales by 2031.

The Novo Nordisk Wegovy pill complicates Lilly's calculus. The Wegovy pill shows ~14 percent weight loss in intent-to-treat populations and ~17 percent when patients stay on treatment. The drug launched at what Novo positions as an aggressive price point, significantly undercutting Wegovy's $1,000+ monthly cost. Novo has also signaled it will bring a higher-dose injectable formulation, "Wegovy-Plus," to market in 2026 to close the weight loss gap with Lilly.

First-mover advantage, aggressive pricing, multiple formulations, and a brand that already resonates with patients after five years of injectable success. Lilly's response isn't to reduce orforglipron's price or accelerate approval timelines since those are largely fixed.

Instead, Lilly is funding Nimbus to develop new molecular scaffolds optimized for obesity and metabolic disease. If orforglipron wins the first wave of the oral obesity market, Nimbus-derived candidates become the second-wave differentiation. If orforglipron underperforms, Lilly has backup candidates already in the pipeline.

Why Does AI-Driven Discovery Matter?

The addressable patient population in the obesity market is massive with over 100 million Americans having obesity, and approximately 1 in 8 US adults currently using GLP-1 medications. The market size is huge and growing rapidly.

The mechanism of action (GLP-1 receptor agonism) is well-validated and understood. But the drug discovery challenge is far from easy, finding small molecules that target difficult-to-drug proteins, that have pharmacokinetic properties suitable for oral delivery, minimize gastrointestinal side effects, and deliver superior weight loss compared to competitors.

This is where Nimbus's computational platform provides value. Traditional drug discovery relies on screening compounds, running assays, and iterating on chemical structures based on actual results. AI-enhanced computational drug discovery compresses that timeline by using machine learning models to predict molecular behavior before synthesis.

Nimbus's "structure-based design" approach integrates 3D atomic-level modeling with AI to identify compounds with optimal properties across multiple dimensions simultaneously. The result is fewer iterations, faster timeline, and a higher probability of success.

For a market racing to establish dominance, timeline acceleration is commercial oxygen. Every month matters, and if Nimbus can deliver a clinical candidate 12–18 months faster than traditional discovery, the commercial implications are profound. Earlier trial initiation, data readout, regulatory submissions, and an earlier market entry.

The TYK2 example shows Nimbus's capability. Tyrosine kinase 2 is a validated psoriasis target, but it's also a target that resists simple inhibition, blocking TYK2 globally causes immune complications. Nimbus's computational platform identified a TYK2 inhibitor with isoform selectivity, the ability to block TYK2 while sparing related kinases, a property that typically requires extraordinary synthetic chemistry to achieve.

Takeda acquired the program for $4 billion, and within three years, the molecule cleared Phase 3 trials. That reflects systematic improvements in drug-like properties, safety optimization, and manufacturing feasibility.

Lilly is banking on the same recipe working for obesity. The AMPK collaboration breakthrough in February 2025 provided additional validation. Nimbus solved a "decades-old challenge" in discovering isoform-specific AMPK activators, compounds that activate only the desired protein isoform while avoiding off-target effects.

Novo Nordisk's first-mover advantage is real. Lilly's orforglipron is formidable. But the market is large enough for multiple winners. Novo Nordisk projects the overall GLP-1 market, including obesity, diabetes, and cardiovascular indications, could exceed $150 billion annually by the early 2030s. Within that envelope, oral formulations represent a multi-billion-dollar subcategory. Patients switching from injectables, patients with needle phobia, and patients preferring daily oral dosing is the addressable patient base for oral obesity drugs is massive.

Under this market dynamic, Lilly's strategy makes economic sense. Orforglipron represents Lilly's primary obesity play. But the Nimbus deal creates optionality. If Nimbus delivers a differentiated obesity candidate, one with superior weight loss, better tolerability, or unique mechanistic properties, Lilly has a portfolio approach to the obesity market.